News | July 28, 2022
Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr
Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022
Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.
The tenure of contract will be upto 10 years from date of signing the contract/installation.
GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022
The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Subscribe To Our Newsletter & Stay Updated
